NanoEntek launches automated high-throughput cell counter for CDMOs

NanoEntek has introduced the EVE-HT A26, a fully automated cell counter aimed at bioprocessing and CDMO customers worldwide. The system is designed to cut processing time, reduce sample volume and remove manual bottlenecks in cell-counting workflows for biopharma and cell therapy manufacturing.

Why it matters: - NanoEntek is targeting the global CDMO market as demand grows in the cell and gene therapy sector. - The EVE-HT A26 is built to reduce manual handling in large-scale bioprocessing, where speed, sample efficiency and consistency can affect manufacturing throughput. - Lower sample requirements can improve yield for high-value cell types and reduce operating costs in research and production settings.

What happened: - NanoEntek launched the EVE-HT A26, a fully automated high-throughput cell counter. - The launch marks NanoEntek’s expansion into the global bioprocessing and CDMO market. - The product is based on the company’s EVE-HT series technology. - A NanoEntek official said the company expects the platform to improve operational efficiency at CDMOs and biopharmaceutical research and manufacturing facilities worldwide.

The details: - EVE-HT A26 automates the full workflow from cell preparation and staining to counting and analysis. - The system uses a 7-axis robotic architecture. - NanoEntek’s Bio-MEMS technology is integrated with linear motor drives and precision robotic pipetting. - The platform can process up to 96 samples in 10 minutes without operator intervention after loading. - Competing systems typically require more than three hours for a similar workflow, according to the release. - EVE-HT A26 uses as little as 20 μL per test. - Competing instruments generally require 170 μL or more per test. - NanoEntek says the lower volume can drive cost savings and better sample yield. - The company is building on supply references with leading global biopharma companies to widen market reach.

Between the lines: - The launch positions NanoEntek against existing high-throughput cell counting platforms by combining automation, speed and lower input volume in one system. - The product pitch is aimed at customers under pressure to scale cell-based manufacturing without adding labor or creating workflow bottlenecks. - The mention of supply references suggests NanoEntek is using existing biopharma relationships to support broader commercial adoption.

What's next: - NanoEntek will likely use the EVE-HT A26 to deepen penetration in biopharma, CDMO and cell therapy manufacturing accounts. - Broader adoption will depend on whether customers validate the claimed speed, efficiency and sample-savings advantages in production environments. - The company is likely to continue leveraging demand in the CGT sector as it expands market reach.